38 results
8-K
EX-99.1
NRBO
NeuroBo Pharmaceuticals Inc
22 Sep 23
Regulation FD Disclosure
8:03am
on Chronic Liver and Related Metabolic Diseases Product Preclinical Phase 1 Phase 2 Upcoming Catalysts DA-1241 (GPR119 Agonist) 2H 2023: initiation of Part 2 … effect ➢ DA-1241 showed no noteworthy safety concerns in safety pharmacology and toxicology studies up to 26 & 39-week chronic dosing in rats
424B4
NRBO
NeuroBo Pharmaceuticals Inc
7 Nov 22
Prospectus supplement with pricing info
9:07am
success of semaglutide (WEGOVY®), a drug recently approved for the treatment of chronic weight management in adults with obesity. With the success … in overnight fasted mice.
In diabetic mice with hypertriglyceridemia, chronic treatment with DA-1241 lowered fasting and non-fasting blood glucose levels
FWP
4fw68tjp52tqky14clcf
24 Oct 22
Free writing prospectus
4:38pm
8-K
EX-99.1
d7sw9 8jkjsf0gfmlozr
15 Nov 21
NeuroBo Pharmaceuticals Reports Third Quarter 2021 Financial Results
8:18am
8-K
EX-99.1
kxmjt o1wllf538piph
4 Nov 21
NeuroBo Pharmaceuticals Appoints Gil Price, M.D. as President
8:10am
8-K
EX-99.1
5doeb3jhe37s
4 Oct 21
Neurobo Pharmaceuticals Announces $14 Million Registered Direct Offering
4:46pm
8-K
EX-99.1
7unuk18n
16 Aug 21
NeuroBo Pharmaceuticals Reports Second Quarter 2021 Financial Results
8:13am
8-K
EX-99.1
i9uj1y
12 Jul 21
NeuroBo Pharmaceuticals’ Shareholders Elect Hyung Heon Kim and Andrew I. Koven to NeuroBo’s Board of Directors
8:41am
8-K
EX-99.1
usfj 7yfs6e8uumt
17 May 21
NeuroBo Pharmaceuticals Reports First Quarter 2021 Financial Results
5:03pm
8-K
EX-99.1
ttb06val3
15 Apr 21
NeuroBo Pharmaceuticals Reports Full Year 2020 Financial Results and Provides Corporate Strategic Update
4:58pm
8-K
EX-99.1
po6xzdbn6m
24 Mar 21
NeuroBo Pharmaceuticals Receives Approval for Amendment of Contingent Value Rights for Gemcabene
8:15am
8-K
EX-99.1
k8rdzl
5 Mar 21
Company Presentation Confidential March 2021
8:41am
8-K
EX-99.2
z2qx m8a0hnoh0
21 Jan 21
NeuroBo Pharmaceuticals Announces $10.0 Million Private Placement
5:03pm